Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters

被引:83
作者
Madec, Y
Boufassa, F
Porter, K
Meyer, L
机构
[1] MRC, Clin Trials Unit, London NW1 2DA, England
[2] Univ Paris 11, Hop Bicetre, Dept Epidemiol, INSERM,U569,INED, F-94276 Le Kremlin Bicetre, France
基金
英国医学研究理事会;
关键词
HIV seroconverters; cohort; undetectable viraemia;
D O I
10.1097/01.aids.0000194134.28135.cd
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To identify factors associated with sustained undetectable viraemia after HIV-1 seroconversion in treatment-naive patients, and to describe concomitant CD4 cell count progression. Methods: Seroconverters enrolled in CASCADE were assumed to control viraemia if at least two consecutive viral load measurements were < 400/500 copies/ml without treatment. Factors associated with undetectable viraemia were identified through a logistic regression. A joint model was used to describe simultaneously the CD4 cell count progression during and after that period and to identify factors associated with sustained undetectable viraemia. Results: Of 2176 seroconverters, 145 (6.7%) spontaneously controlled viraemia. Women were more likely than men to achieve undetectable viraemia [adjusted odds ratio (OR), 2.12; 95% confidence interval (CI), 1.49-3.12] unlike patients who reported a symptomatic primary infection (adjusted OR, 0.58; 95% Cl, 0.36-0.94). AIDS and death rates were significantly lower in patients achieving undetectable viraemia than in the others. The median period of undetectable viraemia was 11.2 months; on average, CD4 cell counts remained stable during that period, and decreased with a mean rate of 5 cells/mu l per month thereafter. High CD4 cell count at the beginning of undetectable viraemia and non-symptomatic primary infection favoured the preservation of undetectable viraemia. Conclusion: A small proportion of seroconverters appeared to be able to control HIV viraemia spontaneously, mostly those without seroconversion illness and within a few years following seroconversion; this is associated with the benefits of slower CD4 cell count decline and improved long-term prognosis. Such persons should be targeted for in depth investigation. (C) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:2001 / 2007
页数:7
相关论文
共 17 条
[1]  
Babiker A, 2000, LANCET, V355, P1131, DOI 10.1016/S0140-6736(00)02061-4
[2]   Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters [J].
Bhaskaran, K ;
Pillay, D ;
Walker, AS ;
Fisher, M ;
Hawkins, D ;
Gilson, R ;
McLean, K ;
Porter, K .
AIDS, 2004, 18 (10) :1471-1473
[3]  
*CASCADE COLL, 1999, J ACQ IMMUN DEF SYND, V32, P303
[4]  
CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration, 2000, HIV Med, V1, P224
[5]  
Delmas MC, 1997, AIDS, V11, P1071
[6]   Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy [J].
García, F ;
Plana, M ;
Vidal, C ;
Cruceta, A ;
O'Brien, WA ;
Pantaleo, G ;
Pumarola, T ;
Gallart, T ;
Miró, JM ;
Gatell, JM .
AIDS, 1999, 13 (11) :F79-F86
[7]   Separate and joint modeling of longitudinal and event time data using standard computer packages [J].
Guo, X ;
Carlin, BP .
AMERICAN STATISTICIAN, 2004, 58 (01) :16-24
[8]   Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy [J].
Harrigan, PR ;
Whaley, M ;
Montaner, JSG .
AIDS, 1999, 13 (08) :F59-F62
[9]   Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection [J].
Hubert, JB ;
Burgard, M ;
Dussaix, E ;
Tamalet, C ;
Deveau, C ;
Le Chenadec, J ;
Chaix, ML ;
Marchadier, E ;
Vildé, JL ;
Delfraissy, JF ;
Meyer, L ;
Rouzioux, C .
AIDS, 2000, 14 (02) :123-131
[10]   HIV controllers: A homogeneous group of HIV-1-infected patients with spontaneous control of viral replication [J].
Lambotte, O ;
Boufassa, F ;
Madec, Y ;
Nguyen, A ;
Goujard, C ;
Meyer, L ;
Rouzioux, C ;
Venet, A ;
Delfraissy, JF .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (07) :1053-1056